
SEER*Educate Announcements For July 2020

Mary Potts, RHIA, CPA, CTR Director, SEER*Educate Fred Hutchinson Cancer Research Center, Cancer Surveillance System Learn by Doing: SEER Workshop and Casefinding (path and scan sources)

SEER Workshop

The SEER Workshop will be held virtually this fall. (SEER to provide more details later this summer.) For those planning to attend, please complete the associated exercises by August 31, 2020. The responses to these exercises will be used to determine which cases should be discussed in greater detail during the workshop.



CEs for completion of these coding exercises have been awarded by NCRA. CEs for completing the exercises are separate from the CEs awarded by attending the workshop.

- NCRA-037, 20 exercises, 3.0 CEs, Dx 2018 Histologies Solid Tumors
- NCRA-036, 10 exercises, 1.5 CEs, Dx 2018 Histologies Heme

For each of those two series, all the exercises for the series must be completed for the CE award. (Partial credit on the case coding will not be awarded.) In addition, a minimum score of 70% is required on each exercise for the CE award. You may retake exercises as necessary.

These are difficult cases selected for advanced training for registrars, but also selected to challenge the coding guidelines – looking for errors, omissions, and ambiguities. Please read the general guidelines of the appropriate manual before you begin working on these exercises.

We do not intend for workshop participants who are experienced registrars to spend more than 8 to 10 minutes per exercise, completing the coding and then reading through the rationale. Newer registrars may find completing an exercise takes a bit longer.

Casefinding – Path sources



How many batches of path exercises are we doing?

Your path practicum tour concludes with Practicums 09-12 released in July 2020.

Under the Training Menu in SEER*Educate is a Casefinding Page with pathology reports to train staff in the application of SEER's reportability rules that also requires a working knowledge of the Solid Tumor Rules, Heme Rules, and ICD-O-3 coding.

During 2019, the first six practicums (600 exercises) were released. During 2020, we released an additional six practicums for a total of 1,200 path casefinding exercises.

This selection of pathology reports is based on the **types of actual reports** that both trainees and sometimes experienced staff at our registry misclassified as to the potential number of primaries (0 for not reportable and then 1, 2, or 3 for reportable primaries).

These pathology reports are not intended to be trick questions but are intended to challenge people. After you declare the number of potentially reportable primaries, you are prompted to code the primary site(s), if any. These exercises provide many opportunities for students and registry staff to practice primary site coding in addition to learning casefinding and how to apply the Solid Tumor Rules and Heme Rules.

Casefinding is always done in context of a facility's reporting requirements for State reporting, CoC reporting (if the facility is ACoS-approved), and per the facility's own Cancer Committee requests. For this purpose, we created SEER*Educate Memorial Hospital. This hospital registry uses a Casefinding Overview document, General Guidelines document, and then a Facility-Specific Path Casefinding Rules document, and these documents are available on the Casefinding Page. Each user needs to read these documents before starting these exercises and then reference the documents as needed throughout the exercises.

The National Cancer Registrars Association (NCRA) recognizes 9 practicum hours for the casefinding requirement for students who complete a set of 100 path reports achieving 85% accuracy across the cases. Although users can immediately repeat a test to improve one's score, we recommend cycling through all 100 in a set before repeating any tests to improve your actual understanding of the casefinding guidelines, reportability rules and resources, and primary site coding.

An example of the detail provided in the rationales is shown below. Reading the rationales and learning the concepts that are repeated throughout these exercises is the transferable skill students and registrars need to acquire to perform highly accurate casefinding.

Example Answer/Rationale for a Pathology Report

CORRECT		CRITICAL (2.00/2.00)
Data Item:	Potentially Reportable	
Response:	2 0	
Correct Answer:	2	

Rationale:

This case is potentially reportable for two primaries per the Final Diagnosis and the Clinical Data section of the pathology report. The Final Diagnosis of the current urethra biopsy was positive for high grade squamous intraepithelial neoplasia/carcinoma in situ. The patient's high grade squamous intraepithelial neoplasia is conclusively stated to be equivalent to in situ disease, so it is synonymous with carcinoma in situ. Carcinoma in situ is a reportable disease process per the ICD-O-3.

The Clinical Data section of the pathology report states the patient has a history of erythroplasia of Queyrat that was previously treated. Queyrat erythroplasia (erythroplasia of Queyrat) is a subtype of squamous cell carcinoma in situ that arises on the penis. Queyrat erythroplasia is a reportable in situ disease process per the ICD-O-3.

The 2018 Solid Tumor Rules, Urinary Multiple Tumors Rules, Note 2 under the Multiple Tumors header, confirms separate, non-contiguous tumors are always multiple primaries when they are in the urinary system AND in a site other than the urinary system. That is, both malignancies arise from distinct primary sites in different schemas. Therefore, a Queyrat erythroplasia of the penis (C60_) is not the same as a urinary primary (C659, C669, C67_, C680-C689). This is also confirmed by Urinary Rule M14 (Abstract multiple primaries when the ICD-O site code differs at the second (C**X**xx) and/or third (Cx**X**x) character).

This case needs to be investigated further to confirm that the patient's erythroplasia of Queyrat has been included in the cancer registry if appropriate. The newly-diagnosed intraepithelial squamous cell carcinoma of the urethra must also be investigated further since it is a reportable in situ disease process.

Note: Central registries are required to follow back to facilities or physicians for any pathology report that mentions a reportable disease currently exists or that indicates the patient had a reportable disease diagnosed in the past if the case is not reflected in the central registry database.


CORRECT		(1.00/1.00)
Data Item:	Primary Site(s)	
Response:	C680 C609	
Correct Answer:	C680 C609	

Rationale:


C680 (Urethra). The urethra was specified as the primary site of the patient's current high grade squamous intraepithelial neoplasia/carcinoma in situ per the Final Diagnosis and Clinical Data section of the pathology report. Code the primary site documented in the pathology report. Code the primary site to C680 (Urethra).

C609 (Penis, NOS). Queyrat erythroplasia has a site-associated code listed in the ICD-O-3. The site-associated code for Queyrat erythroplasia is the penis (C60_). The Summary of Principal Rules for Using ICD-O-3, Rule H (Site-Associated Morphology Terms) instructs one to use the suggested code if no site is indicated in the diagnosis. The specific penis subsite from which the Queyrat erythroplasia arose is unknown, so the primary site is coded as C609 (Penis, NOS).

Where do I find them? Under Training Menu, Casefinding Tests



Is there a report? Under Reports, View Excel Reports



Are there CEs? No

No CEs are available for the path practicum exercises; however, going through one set of 100 path reports can be beneficial even for experienced registrars if your schedules permit.

Casefinding – Scan sources

Users requested casefinding exercises be developed with non-path sources. The scan casefinding modules will be released in October, November and December 2020. There will be 50 cases in each monthly module release.

Log in or sign up at SEER*Educate today by visiting https://educate.fredhutch.org/ and Learn by Doing!

SEER*Educate is funded by Surveillance, Epidemiology and End Results (SEER) of the National Cancer Institute (NCI) and the Fred Hutchinson Cancer Research Center. (NCI Contract Number HHSN261201800004I)